RVV Revive Therapeutics Ltd

Revive Therapeutics Ltd. (TSX VENTURE:RVV) ("Revive") reports that in view of
the recent market activity in Revive's shares, the Investment Industry
Regulatory Organization of Canada ("IIROC") has contacted Revive in accordance
with its usual practice. While Revive ordinarily does not comment on market
activity or market rumors, Revive confirms that it is not aware of any
developments that would merit such trading activity.


About Revive Therapeutics Ltd.

Revive Therapeutics Ltd. is a Canadian public company (TSX VENTURE:RVV) focused
on acquiring, developing and commercializing treatments for major market
opportunities such as gout, postoperative pain, and rare diseases. Revive aims
to bring drugs to market by finding new uses for old drugs, also known as drug
repurposing or drug repositioning, and improving the therapeutic performance of
existing drugs for underserved medical needs. Additional information on Revive
is available at www.revivethera.com.


The information in this news release includes certain information and statements
about management's view of future events, expectations, plans and prospects that
constitute forward looking statements that may not be based on historical fact,
including without limitation statements containing the words "believe", "may",
"plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and
similar expressions. These statements are based upon assumptions that are
subject to significant risks and uncertainties. Because of these risks and
uncertainties and as a result of a variety of factors, the actual results,
expectations, achievements or performance may differ materially from those
anticipated and indicated by these forward looking statements. Such factors
include, among others, Revive's stage of development, lack of any product
revenues, additional capital requirements, risk associated with the completion
of clinical trials and obtaining regulatory approval to market products, the
ability to protect intellectual property, dependence on business partners and
the prospects for negotiating joint ventures, distribution and licensing
arrangements and their timing. Specifically, certain risks and uncertainties
that could cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially from any future
events or results expressed or implied by such statements and information
include, but are not limited to; the risks and uncertainties that Revive may not
be able to successfully develop and obtain regulatory approval for its products;
intellectual property disputes; future operating results are uncertain and
likely to fluctuate; ability to raise additional capital; successfully
establishing additional corporate collaborations, distribution or licensing
arrangements; establishing marketing and the costs of launching products may be
restricting; Revive's lack of experience in commercial manufacturing; increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in Revive's filings on SEDAR (www.sedar.com), including,
without limitation, Revive's Filing Statement dated November 26, 2013 filed on
SEDAR on November 27, 2013. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.



Although Revive believes that the expectations reflected in forward looking
statements are reasonable, it can give no assurances that the expectations of
any forward looking statements will prove to be correct. Except as required by
law, Revive disclaims any intention and assumes no obligation to update or
revise any forward looking statements to reflect actual results, whether as a
result of new information, future events, changes in assumptions, changes in
factors affecting such forward looking statements or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Revive Therapeutics Ltd.
Fabio Chianelli
Chief Executive Officer
905-605-5535 (ext. 10)
fabio@revivethera.com
www.revivethera.com

Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Mar 2024 to Apr 2024

Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Apr 2023 to Apr 2024